Bayer 1Q earnings rose – Short term trend bullish

Bayer, the German pharmaceutical and life sciences company, reported that 1Q net income rose 20.0% on year to 1.49 billion euros.

Trader 3

Bayer, the German pharmaceutical and life sciences company, reported that 1Q net income rose 20.0% on year to 1.49 billion euros and adjusted EBITDA grew 10.2% to 4.39 billion euros on revenue of 12.85 billion euros, up 4.8% (+6.0% on a currency and portfolio adjusted basis). The company added: "Bayer anticipates that, following the positive start to the year, COVID-19 will continue to impact its business over the course of 2020. It will not be possible to reliably assess the positive and negative effects until later in the year."

From a technical perspective, the stock price remains in a short term up trend within a bullish channel. Prices have broken above the declining 50-day simple moving average thanks to a bullish gap. The daily Relative Strength Index (RSI, 14) is bullish and not overbought. The bias remains bullish as long as 55.6E is support. Next resistance thresholds are set at 64E and 68E. 

Alternatively, a break below 55.6E would call for a reversal down trend with 50 as target.

Source: GAIN Capital, TradingView

Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.

Open an Account